Scalper1 News
United Therapeutics (UTHR) early Tuesday topped fourth-quarter sales and profit views, as the maker of therapies to treat cardiovascular disease, infectious diseases and cancer benefited from a strong performance from its new Orenitram drug to treat high blood pressure. United Therapeutics logged fourth-quarter earnings of $2.17 a share. That reversed a 60-cent per-share loss in the year-earlier quarter and Wall Street consensus estimates by 7 Scalper1 News
Scalper1 News